Karuna Therapeutics, Inc.
KRTXDrugs in Pipeline
2
Phase 3 Programs
2
Upcoming Catalysts
0
Next Catalyst
None scheduled
Market Overview
Stock performance and key metrics
0 upcoming, 0 past
No catalysts found.
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
Xanomeline and Trospium Chloride Capsules | Phase 3 | Schizophrenia | - | - |
KarXT | Phase 3 | Schizophrenia | - | - |
Frequently asked questions
What is in Karuna Therapeutics, Inc.'s drug pipeline?→
CatalystAlert tracks 2 drug candidates in Karuna Therapeutics, Inc.'s (KRTX) pipeline across Phase 3. Its lead program is Xanomeline and Trospium Chloride Capsules (Phase 3). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Karuna Therapeutics, Inc.'s next FDA catalyst?→
CatalystAlert tracks every upcoming catalyst for Karuna Therapeutics, Inc. (KRTX) — PDUFA decision dates, Phase 1/2/3 trial readouts, FDA advisory committee meetings and NDA/BLA filings — each confidence-rated as confirmed, estimated or AI-detected.
How do I track KRTX biotech catalysts?→
Add KRTX to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Karuna Therapeutics, Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.